Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Funding topics include HIV criminalization, “bathroom bills,” the rural South and ACT UP.
A modeling study suggests that HIV meds’ effects on the immune response may partially explain the recent rise in syphilis in gay and bi men.
The fight against the virus has always been a struggle. This election did not change that fundamental truth.
The use of Truvada as PrEP appears likely to have helped drive a 40 percent one-year drop in HIV diagnoses at the London clinic.
The much-celebrated HIV prevention pill is failing to reach those at highest risk for the virus: Black men who have sex with men.
New trial compares Descovy to Truvada.
Plus: Find your HIV risk score on the PrEP Here website, flaunt an Andrew Christian T-shirt and check out this billboard.
The cohort study also found that older individuals on PrEP were at greater risk of reduced kidney function.
A city campaign wants women to take control of their sexuality and health—and know PrEP is an option.
Intarcia Therapeutics develops tiny implants that release meds. Here’s why they may be better than daily pills.
The global trial of 4,500 trans women and cis men who have sex with men will see whether cabotegravir prevents HIV as well as daily Truvada.
Various internal and logistical obstacles likely impede the uptake of and adherence to daily PrEP as HIV prevention among gay and bi men.
An educator and advocate wants the HIV community to have some honest conversations.
Following a syphilis diagnosis, HIV-negative men who have sex with men at a London clinic contracted HIV at a high rate.
Lifting the entry ban for tourists and immigrants with HIV, releasing the National HIV/AIDS Strategy, approving PrEP, and more.